Skip to main content

Table 2 Cost and disability weight inputs for the high burden countries analyzed, US$ 2013a

From: Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries

Parameter

Country

Estonia

Russia

South Africa

Peru

China

Philippines

India

Cost of treatment per month, US$ [source]

 Cost of BR (intensive)

141 [20, 25]

273 [18]

167 [25, 36]

149 [22]

78 [23]

134 [25]

95 [37]

 Cost of BR (continuation)

78 [20;25]

183 [18]

49 [25, 36]

71 [22]

26 [23]

88 [25]

40 [37]

Cost of monitoring per month, US$ [source]

 Bedaquiline + BR

Intensive phase

109 [20]

122 [19]

81 [26]

81 [21]

63 [23]

65b

44 [38, 39]

Continuation phase

98 [20]

94 [19]

64 [26]

70 [21]

55 [23]

595b

36 [38, 39]

 BR only

Intensive phase

101 [20]

100 [19]

65 [26]

68 [21]

60 [23]

59b

43 [38, 39]

Continuation phase

90 [20]

72 [19]

48 [26]

57 [21]

52 [23]

53b

35 [38, 39]

Cost of inpatient and outpatient care, US$ [source]

 Cost of hospitalization for initial MDR-TB per day

268 [24]

231 [18]

84 [26]

55 [21]

38 [24]

20 [24]

16 [30]

 Cost of outpatient care for initial MDR-TB

No. of consultation per month (mean)/unit cost

1/41 [24]

1/36 [24]

1/17 [26]

1/11 [21]

1/9 [24]

1/6 [24]

1/3 [30]

No. of TB nurse home visits per month (mean)/unit cost

28/1 [24]

28/0 [24]

28/NA [26]

28/NA [21]

28/NA [24]

28/NA [24]

28/NA [30]

Disability weights (mean) by health state for all countries analyzed

 Active TB

0.331 [16]

 Culture converted TB (first year)

0.170 [16]

 Culture converted TB (subsequent year)

0.170 [16]

 Lost to follow-up

0.331 (Assumed equal to the active MDR-TB state)

 Treatment complete and cured

0 (Assumed equal to the general population [41])

 Death

1

  1. BR background regimen, MDR-TB multidrug-resistant tuberculosis, NA Not available, US United States
  2. aAll costs have been converted and inflated to 2013 US$
  3. bSOURCE: local hospital